Q3 FY2026 · ended Sep 30, 2026 · Revenue $0 · Filed Nov 5, 2026
vTv Therapeutics Inc. (VTVT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $11.6 million.
Revenue
$0
Net income
$-11.62M
-33.6% vs year-ago quarter
Operating cash flow
$-10.19M
-95.1% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
0
Net cash
$88.93M
Q4 FY2025
Operating margin
-29.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTVT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- High Point, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1641489
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $36.8M | $0 | $0 |
| Operating income | -$12.4M | -$13.9M | $23.3M | -$7.9M | -$10.7M |
| Net income | -$11.6M | -$13.1M | $24.1M | -$7.1M | -$8.7M |
| Operating cash flow | -$10.2M | -$11.4M | $9.2M | -$9.3M | -$5.2M |
| Total assets | $78.6M | $87.6M | $98.8M | $89.9M | $99.5M |
| Total liabilities | $8.9M | $9.0M | $8.9M | $25.5M | $29.0M |
| Stockholders' equity | $69.7M | $78.6M | $90.0M | $64.4M | $70.5M |
| Cash and investments | $77.2M | $86.6M | $98.1M | $88.9M | $98.5M |
| Total debt | — | — | — | $0 | $32,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 6, 2026 | Oct 1, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 26, 2026 |
All 601 vTv Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.